FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951677496> ?p ?o ?g. }

• W2951677496 endingPage "156" @default.
• W2951677496 startingPage "154" @default.
• W2951677496 abstract "Introduction: Relapsed or refractory (R/R) follicular lymphoma (FL) remains an area of unmet medical need and treatments with novel mechanisms of action are desirable. The histone methyltransferase EZH2 is an important regulator of the germinal center (GC) reaction that is involved in preventing terminal differentiation of GC B-cells. EZH2 activating mutations are present in ~20% of FL patients (pts) and are postulated to be oncogenic drivers. Tazemetostat, a selective, oral EZH2 inhibitor has shown antitumor activity in a phase 1/2 study that included non-Hodgkin lymphoma pts with mutant (MT) or wild-type (WT) EZH2tumors, providing rationale for further investigation. Methods: This open-label, multicenter, phase 2 study of tazemetostat enrolled pts with either MT or WT EZH2 R/R diffuse large B-cell lymphoma or FL (Grade 1-3b). Key inclusion criteria included: age ≥18 years, ≥2 prior treatment regimens, and measurable disease. Tumor tissue was analyzed for EZH2 hot spot activating mutations (Y646X, A682G, A692V) using a cobas® EZH2 Mutation Test (Roche Molecular Systems, investigational use only). Tazemetostat 800 mg was administered orally, twice daily. Response was assessed every 8 weeks using 2007 IWG-NHL criteria. The primary endpoint was ORR (CR + PR). Secondary endpoints included PFS and safety/tolerability. Efficacy and safety were analyzed for the EZH2 MT and EZH2 WT groups. Results: As of February 1, 2019, interim data were summarized from 95 FL pts (41 EZH2 MT and 54 EZH2 WT). The overall median age was 61 years, and median prior lines of therapy was 2 (range: 0-11) in the EZH2 MT group and 3 (range: 1-8) in the EZH2 WT group. Median follow-up times, ORR, median duration of response for 92 response evaluable patients in both EZH2 MT and WT groups are highlighted in the table. Response duration was greater than 24 weeks in 83% of pts, and 50% of pts had a response duration greater than 1 year. Treatment-emergent adverse events (TEAEs) leading to dose reductions occurred in 8% of pts and study drug discontinuation due to TEAEs occurred in 9% of FL pts. The overall safety profile was similar to what has been previously reported. Grade ≥3 treatment-related TEAEs were reported in 18% of pts; no Grade 5 AEs were reported. Keywords: follicular lymphoma (FL); germinal center B cell-like (GCB). Disclosures: Morschhauser, F: Consultant Advisory Role: Gilead, Servier, Roche/Genentech; Honoraria: Celgene, BMS, Janssen. Tilly, H: Consultant Advisory Role: Celgene, Astra-Zeneca, Karyopharm, Roche; Honoraria: BMS, Janssen, Gilead; Research Funding: Celgene. Phillips, T: Consultant Advisory Role: Genentech, Gilead, Bayer, Seattle Genetics, Pharmacyclics; Research Funding: Pharmacyclics, Abbvie. Ribrag, V: Consultant Advisory Role: Epizyme, Servier, Nanostring, Gilead, Pharmamar, BMS, MSD, Incyte, Roche, Infinity; Honoraria: ESAI; Research Funding: Epizyme, ArgenX. Jurczak, W: Consultant Advisory Role: AstraZeneca/Acerta, European Medicines Agency, Sandoz-Nowartis, Janssen, Gilead; Research Funding: Afimed, BeiGene, Celgene, Epizyme, AstraZeneca/Acerta. McKay, P: Consultant Advisory Role: Epizyme; Honoraria: Epizyme. Opat, S: Consultant Advisory Role: Roche, Celgene, Mundipharma, Janssen; Honoraria: Roche, Celgene, Mundipharma, Janssen. Radford, J: Consultant Advisory Role: Takeda, Bristol-Myers Squibb, Seattle Genetics, Novartis; Stock Ownership: GSK, AstraZeneca; Honoraria: Takeda; Research Funding: Takeda, Pfizer, ADC Therapeutics, Celgene, AstraZeneca. Rajarethinam, A: Employment Leadership Position: Epizyme, Inc; Stock Ownership: Epizyme, Inc. Yang, J: Employment Leadership Position: Epizyme, Inc; Stock Ownership: Epizyme, Inc. Howell, H: Employment Leadership Position: Epizyme, Inc; Stock Ownership: Epizyme, Inc. Newberry, K: Employment Leadership Position: Epizyme, Inc; Stock Ownership: Epizyme, Inc. Adib, D: Employment Leadership Position: Epizyme, Inc; Stock Ownership: Epizyme, Inc. Salles, G: Honoraria: Roche, Jannsen, Gilead, Celgene, Novartis, Amgen, BMS, Merck, Servier." @default.
• W2951677496 created "2019-06-27" @default.
• W2951677496 creator A5003078312 @default.
• W2951677496 creator A5011398209 @default.
• W2951677496 creator A5016764336 @default.
• W2951677496 creator A5027520603 @default.
• W2951677496 creator A5030547203 @default.
• W2951677496 creator A5032462496 @default.
• W2951677496 creator A5034090582 @default.
• W2951677496 creator A5037480549 @default.
• W2951677496 creator A5043214062 @default.
• W2951677496 creator A5046659441 @default.
• W2951677496 creator A5051605599 @default.
• W2951677496 creator A5055441745 @default.
• W2951677496 creator A5062534813 @default.
• W2951677496 creator A5074376018 @default.
• W2951677496 creator A5081516632 @default.
• W2951677496 creator A5090205721 @default.
• W2951677496 creator A5090258495 @default.
• W2951677496 date "2019-06-01" @default.
• W2951677496 modified "2023-10-16" @default.
• W2951677496 title "INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA" @default.
• W2951677496 doi "https://doi.org/10.1002/hon.111_2629" @default.
• W2951677496 hasPublicationYear "2019" @default.
• W2951677496 type Work @default.
• W2951677496 sameAs 2951677496 @default.
• W2951677496 citedByCount "11" @default.
• W2951677496 countsByYear W29516774962019 @default.
• W2951677496 countsByYear W29516774962020 @default.
• W2951677496 countsByYear W29516774962021 @default.
• W2951677496 countsByYear W29516774962023 @default.
• W2951677496 crossrefType "journal-article" @default.
• W2951677496 hasAuthorship W2951677496A5003078312 @default.
• W2951677496 hasAuthorship W2951677496A5011398209 @default.
• W2951677496 hasAuthorship W2951677496A5016764336 @default.
• W2951677496 hasAuthorship W2951677496A5027520603 @default.
• W2951677496 hasAuthorship W2951677496A5030547203 @default.
• W2951677496 hasAuthorship W2951677496A5032462496 @default.
• W2951677496 hasAuthorship W2951677496A5034090582 @default.
• W2951677496 hasAuthorship W2951677496A5037480549 @default.
• W2951677496 hasAuthorship W2951677496A5043214062 @default.
• W2951677496 hasAuthorship W2951677496A5046659441 @default.
• W2951677496 hasAuthorship W2951677496A5051605599 @default.
• W2951677496 hasAuthorship W2951677496A5055441745 @default.
• W2951677496 hasAuthorship W2951677496A5062534813 @default.
• W2951677496 hasAuthorship W2951677496A5074376018 @default.
• W2951677496 hasAuthorship W2951677496A5081516632 @default.
• W2951677496 hasAuthorship W2951677496A5090205721 @default.
• W2951677496 hasAuthorship W2951677496A5090258495 @default.
• W2951677496 hasBestOaLocation W29516774962 @default.
• W2951677496 hasConcept C104317684 @default.
• W2951677496 hasConcept C121332964 @default.
• W2951677496 hasConcept C126322002 @default.
• W2951677496 hasConcept C142424586 @default.
• W2951677496 hasConcept C143998085 @default.
• W2951677496 hasConcept C185592680 @default.
• W2951677496 hasConcept C197934379 @default.
• W2951677496 hasConcept C203092338 @default.
• W2951677496 hasConcept C2777058707 @default.
• W2951677496 hasConcept C2778375690 @default.
• W2951677496 hasConcept C2779338263 @default.
• W2951677496 hasConcept C31760486 @default.
• W2951677496 hasConcept C33288867 @default.
• W2951677496 hasConcept C50171091 @default.
• W2951677496 hasConcept C535046627 @default.
• W2951677496 hasConcept C55493867 @default.
• W2951677496 hasConcept C61943457 @default.
• W2951677496 hasConcept C71924100 @default.
• W2951677496 hasConcept C87355193 @default.
• W2951677496 hasConcept C98274493 @default.
• W2951677496 hasConceptScore W2951677496C104317684 @default.
• W2951677496 hasConceptScore W2951677496C121332964 @default.
• W2951677496 hasConceptScore W2951677496C126322002 @default.
• W2951677496 hasConceptScore W2951677496C142424586 @default.
• W2951677496 hasConceptScore W2951677496C143998085 @default.
• W2951677496 hasConceptScore W2951677496C185592680 @default.
• W2951677496 hasConceptScore W2951677496C197934379 @default.
• W2951677496 hasConceptScore W2951677496C203092338 @default.
• W2951677496 hasConceptScore W2951677496C2777058707 @default.
• W2951677496 hasConceptScore W2951677496C2778375690 @default.
• W2951677496 hasConceptScore W2951677496C2779338263 @default.
• W2951677496 hasConceptScore W2951677496C31760486 @default.
• W2951677496 hasConceptScore W2951677496C33288867 @default.
• W2951677496 hasConceptScore W2951677496C50171091 @default.
• W2951677496 hasConceptScore W2951677496C535046627 @default.
• W2951677496 hasConceptScore W2951677496C55493867 @default.
• W2951677496 hasConceptScore W2951677496C61943457 @default.
• W2951677496 hasConceptScore W2951677496C71924100 @default.
• W2951677496 hasConceptScore W2951677496C87355193 @default.
• W2951677496 hasConceptScore W2951677496C98274493 @default.
• W2951677496 hasIssue "S2" @default.
• W2951677496 hasLocation W29516774961 @default.
• W2951677496 hasLocation W29516774962 @default.
• W2951677496 hasOpenAccess W2951677496 @default.
• W2951677496 hasPrimaryLocation W29516774961 @default.
• W2951677496 hasRelatedWork W1906314377 @default.
• W2951677496 hasRelatedWork W2053485995 @default.
• W2951677496 hasRelatedWork W2107697672 @default.

• next